share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Goodman Tony

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Adial Pharmaceuticals | 4：持股變動聲明
美股SEC公告 ·  03/28 06:10
牛牛AI助理已提取核心訊息
Tony Goodman, the Chief Operating Officer of Adial Pharmaceuticals, Inc. (ADIL), was reported to have engaged in a transaction involving the company's stock on March 25, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of the shares, were not disclosed in the announcement. The number of shares held by Goodman after the transaction was also not provided. This information is crucial for investors to understand the insider activity within Adial Pharmaceuticals and may influence their investment decisions.
Tony Goodman, the Chief Operating Officer of Adial Pharmaceuticals, Inc. (ADIL), was reported to have engaged in a transaction involving the company's stock on March 25, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of the shares, were not disclosed in the announcement. The number of shares held by Goodman after the transaction was also not provided. This information is crucial for investors to understand the insider activity within Adial Pharmaceuticals and may influence their investment decisions.
據報道，阿迪爾製藥公司（ADIL）首席運營官託尼·古德曼於2024年3月25日參與了一項涉及該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和股票總價值。也沒有提供交易後古德曼持有的股票數量。這些信息對於投資者了解Adial Pharmicals內部活動至關重要，並可能影響他們的投資決策。
據報道，阿迪爾製藥公司（ADIL）首席運營官託尼·古德曼於2024年3月25日參與了一項涉及該公司股票的交易。公告中未披露該交易的具體細節，包括股票數量、股票性質、交易價格和股票總價值。也沒有提供交易後古德曼持有的股票數量。這些信息對於投資者了解Adial Pharmicals內部活動至關重要，並可能影響他們的投資決策。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。